Physician profile
Jiri Brabec
NPI 1093944332
$4,215.09
in general payments reported to CMS, 2019-2025
29 companies · $1,412 in 2025
The $1,412 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $816 · 2020: $425 · 2021: $147 · 2022: $31.41 · 2023: $331 · 2024: $1,052 · 2025: $1,412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,705 · Education: $91.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,704.58 |
| Education | $91.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $542.49 | 2021-2025 | Qulipta, Ubrelvy |
| Teva Pharmaceuticals USA, INC. | $500.87 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Supernus Pharmaceuticals, INC. | $464.88 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $276.44 | 2019-2025 | |
| Sk Life Science, INC. | $269.79 | 2021-2025 | |
| Pfizer INC. | $244.05 | 2023-2025 | |
| Allergan, INC. | $240.38 | 2019-2020 | |
| Lilly USA, LLC | $201.62 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Lundbeck LLC | $196.22 | 2024-2025 | Vyepti |
| Amneal Pharmaceuticals LLC | $178.26 | 2024-2025 | Crexont, Ongentys, Rytary |
| Argenx US, INC. | $136.28 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Merz Pharmaceuticals, LLC | $129.50 | 2024-2025 | Xeomin |
| Ucb, INC. | $115.29 | 2024-2025 | Briviact, Zilbrysq |
| Ipsen Biopharmaceuticals, INC | $86.18 | 2019-2025 | Dysport |
| Kyowa Kirin, INC. | $82.36 | 2020-2024 | Nourianz |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $81.43 | 2019-2020 | |
| Biogen, INC. | $75.48 | 2021-2025 | Vumerity, Tysabri, Zurzuvae |
| Ge Healthcare | $68.09 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.89 | 2024-2025 | Caplyta |
| Alexion Pharmaceuticals, INC. | $50.17 | 2024 | Ultomiris |
| Biohaven Pharmaceuticals, INC. | $45.30 | 2021 | |
| Grifols USA, LLC | $34.05 | 2020 | |
| Vertical Pharmaceuticals, LLC | $26.28 | 2019 | |
| Averitas Pharma INC. | $24.68 | 2025 | Qutenza |
| Acadia Pharmaceuticals INC | $22.62 | 2025 | Nuplazid |
| Acorda Therapeutics, INC | $19.25 | 2019 | |
| Mdd US Operations, LLC | $16.30 | 2023 | Gocovri |
| E.R. Squibb & Sons, L.L.C. | $15.05 | 2025 | Cobenfy |
| Genentech USA, INC. | $13.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jiri Brabec listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.